HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 51, 50190-50197, December 20, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/51/50190    most recent M209210200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nandan, D. Articles by Reiner, N. E. Search for Related Content PubMed PubMed Citation Articles by Nandan, D. Articles by Reiner, N. E. Social Bookmarking                      What's this?

Leishmania EF-1 Activates the Src Homology 2 Domain Containing Tyrosine Phosphatase SHP-1 Leading to Macrophage Deactivation^*

Devki Nandan^§, Taolin Yi^¶, Martin Lopez, Crystal Lai, and Neil E. Reiner^**

From the  Department of Medicine, Division of Infectious Diseases, and the  Department of Microbiology and Immunology, The University of British Columbia, Faculties of Medicine and Science, The Research Institute of the Vancouver Hospital and Health Sciences Center, Vancouver, British Columbia V5Z 3J5, Canada and the ^¶ Lerner Research Institute NB4-67, Cleveland Clinic Foundation, Cleveland, Ohio 44195

Received for publication, September 9, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The human leishmaniasis are persistent infections of macrophages caused by protozoa of the genus Leishmania. The chronic nature of these infections is in part related to induction of macrophage deactivation, linked to activation of the Src homology 2 domain containing tyrosine phosphatase-1 (SHP-1) in infected cells. To investigate the mechanism of SHP-1 activation, lysates of Leishmania donovani promastigotes were subjected to SHP-1 affinity chromatography and proteins bound to the matrix were sequenced by mass spectrometry. This resulted in the identification of Leishmania elongation factor-1 (EF-1) as a SHP-1-binding protein. Purified Leishmania EF-1, but not host cell EF-1, bound directly to SHP-1 in vitro leading to its activation. Three independent lines of evidence indicated that Leishmania EF-1 may be exported from the phagosome thereby enabling targeting of host SHP-1. First, cytosolic fractions prepared from macrophages infected with [³⁵S]methionine-labeled organisms contained Leishmania EF-1. Second, confocal, fluorescence microscopy using Leishmania-specific antisera detected Leishmania EF-1 in the cytosol of infected cells. Third, co-immunoprecipitation showed that Leishmania EF-1 was associated with SHP-1 in vivo in infected cells. Finally, introduction of purified Leishmania EF-1, but not the corresponding host protein into macrophages activated SHP-1 and blocked the induction of inducible nitric-oxide synthase expression in response to interferon-. Thus, Leishmania EF-1 is identified as a novel SHP-1-binding and activating protein that recapitulates the deactivated phenotype of infected macrophages.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

According to the latest WHO report, 12 million people are affected by leishmaniasis worldwide and 2 million new cases occur each year (Leishmaniases Control, www.who.int/health-topics/leishmaniasis.htm, updated 2000). Moreover, the incidence of the leishmaniasis has been on the rise because of multiple factors including the AIDS epidemic, increased international travel, lack of effective vaccines, difficulty in controlling vectors, international conflicts, and the development of resistance to chemotherapy. Progress in controlling the leishmaniasis will require improved understanding of pathogenesis to identify novel drug targets or vaccine candidates.

Leishmania donovani is the major causative agent of human visceral leishmaniasis. Leishmania live as either extracellular, flagellated promastigotes in the digestive tracts of their sand fly vectors or as nonflagellated amastigotes within macrophages, where they survive and replicate within phagolysosomes. Macrophages as part of both the innate and acquired immune systems are programmed to ingest and destroy intracellular pathogens. Hence, the mechanisms used by Leishmania and other intracellular pathogens to evade elimination by macrophages are important issues in cell biology and immunology. Infected macrophages are often refractory to cell activation (1, 2) and recent evidence suggests that this is related to impaired cell signaling (1-4) brought about by the action of protein-tyrosine phosphatase (5). In particular, several lines of evidence have converged to establish a role for the host macrophage Src homology 2 domain containing protein tyrosine phosphatase-1 (SHP-1)¹ in the pathogenesis of infection with Leishmania (4, 6-9). Notably, infected macrophages show increased SHP-1 activity and inhibition of tyrosine phosphatase activity reverses the abnormal phenotype of infected cells (4). Moreover, resistance to Leishmania infection is enhanced in SHP-1-deficient macrophages and mice (8). The argument that activation of host SHP-1 is involved in the pathogenesis of infection with Leishmania is also supported by the recent finding that the first-line anti-leishmanial agent used clinically, sodium stibogluconate, is an inhibitor of SHP-1 (10).

Although much is known about the mechanisms that regulate SHP-1 activation, few discrete SHP-1 activating ligands have been identified (11, 12). Here, we show that elongation factor-1 (EF-1) of L. donovani is a novel SHP-1-binding protein and SHP-1 activator, properties not shared by the corresponding host protein. The results also show that introduction of Leishmania EF-1, but not host EF-1 into cells, recapitulates the deactivated phenotype of Leishmania-infected macrophages. These findings identify Leishmania EF-1 as a novel, candidate virulence factor.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Reagents and Chemicals-- RPMI 1640, Hanks' balanced salt solution, and protease inhibitors (phenylmethylsulfonyl fluoride, aprotinin, pepstatin A, and leupeptin), 1,4-diazabiocyclo[2.2.2]octane, DEAE-Sepharose, CM-Sepharose CL-6B, cellulose phosphate (fibrous form), anti-mouse IgG-fluorescein, and calmodulin-agarose were obtained from Sigma. Medium 199 was from Invitrogen. The RAW 264.7 cell line was from the American Type Culture Collection (Rockville, MD). Anti-EF-1 was from Upstate Biotechnology Inc. (Lake Placid, NY). Anti-iNOS and anti-cathepsin D were from Santa Cruz Biotechnology Inc., Santa Cruz, CA. Horseradish peroxidase-conjugated goat anti-mouse antibodies, protein G-agarose, and electrophoresis reagents and supplies were from Bio-Rad. Enhanced chemiluminescence (ECL) reagents were from Amersham Biosciences. Preparation of the GST-SHP-1 construct, its expression and purification has previously been described (13). Protein delivery system Profect 1 was obtained from Targeting System, Santee, CA.

L. donovani-- Amastigotes of the Sudan strain 2S of L. donovani were maintained by serial intracardiac inoculation of amastigotes into female Syrian hamsters. Amastigotes were isolated from the spleens of hamsters infected 4 to 6 weeks earlier as described previously (14). Promastigotes were prepared from freshly isolated amastigotes from spleens of infected hamsters by culturing in medium 199 supplemented with 10% (v/v) heat-inactivated fetal bovine serum, penicillin (100 units/ml), streptomycin (100 µg/ml), adenosine (1 mM), folic acid (10 µg/ml), and hemin (6 µg/ml) at room temperature. Promastigotes were maintained in the laboratory by transferring every third day in medium 199 supplemented as described above. For most experiments, parasites in stationary phase (day 5 containing ~50 × 10⁶ per ml) were used.

Cell Culture-- The murine macrophage cell line RAW 264.7 was cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 µg/ml) at 37 °C in a humidified atmosphere (5% CO₂).

Infection of RAW Cells with L. donovani-- Exponentially growing RAW cells were infected with either stationary phase promastigotes or freshly isolated amastigotes at a parasite to cell ratio of ~10:1. After incubation at 37 °C and 5% CO₂, noninternalized parasites were removed by washing with Hanks' balanced salt solution. To determine the rate of infection, cytospin preparations were prepared from dislodged cells, which were stained with Diff-Quik.

GST-SHP-1 Affinity Chromatography-- Leishmania promastigotes (2-3 × 10⁹) were lysed in ice-cold lysis buffer A (50 mM Tris, pH 7.5, 0.5% Triton X-100, and 20 mM NaCl) containing a mixture of protease inhibitors for 20 min on ice. All subsequent steps were performed at 4 °C. Lysates were centrifuged in a microcentrifuge at maximum speed for 10 min and supernatants were incubated with GST-SHP-1 affinity beads with end-over-end rotation for 2 h. After incubation, affinity beads were transferred to a column and washed extensively. Bound proteins were released with buffer A containing 0.5 M NaCl. An aliquot of partially purified SHP-1 bound proteins was subjected to SDS-PAGE (12%) followed by silver staining.

Immunoprecipitation and Immunoblotting-- L. donovani promastigotes in stationary phase were collected by centrifugation and washed twice with Tris-buffered saline, pH 7.4, and immediately processed for immunoprecipitation. For immunoprecipitation of EF-1, parasites were lysed on ice in lysis buffer B (50 mM Tris, pH 7.4, 1% Triton X-100, 0.15 M NaCl, 1 mM EGTA, 5 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 µg of aprotinin/ml, 10 µg of leupeptin/ml, and 2 µg of pepstatin A/ml). Cell lysates were clarified by centrifugation in a microcentrifuge at maximum speed for 20 min at 4 °C. The resulting supernatants were incubated with anti-EF-1 antibodies for 16 to 18 h at 4 °C. After incubation with antibodies, protein G-agarose was added for 2 h at 4 °C for recovery of immune complexes. After extensive washing, immune complexes were released by boiling agarose beads in SDS sample buffer without -mercaptoethanol. Samples were analyzed by 7.5% SDS-polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose membranes. The membranes were blocked with 3% nonfat dry milk in phosphate-buffered saline followed by incubation with anti-EF-1 antibodies. After washing, the blots were incubated with anti-mouse horseradish peroxidase-conjugated antibody, and developed using the ECL detection system.

Purification of EF-1 from L. donovani Promastigote and RAW Cells-- All operations were carried out at 4 °C unless otherwise indicated. Approximately 1 × 10⁸ exponentially growing RAW cells and 3 × 10⁹ stationary phase L. donovani promastigotes were washed extensively with Hanks' salt solution and suspended separately in 10 ml of ice-cold buffer C (50 mM Tris, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, and 20% glycerol) containing a mixture of protease and phosphatase inhibitors as described above for immunoprecipitation. Cells were sonicated to prepare a cell lysate and centrifuged at 100,000 × g for 20 min. The supernatant was applied to a DEAE-Sepharose column connected to the CM-Sepharose column previously equilibrated in buffer C containing 50 mM KCl. The columns were washed with equilibration buffer until all nonbound proteins had eluted. After disconnection of the CM-Sepharose column, bound proteins on this column were eluted with increasing KCl concentration in buffer C. The fractions containing EF-1 as analyzed on SDS-PAGE followed by immunoblotting using anti-EF-1, were pooled and dialyzed overnight against buffer C without KCl. The dialyzed material was then applied to a phosphocellulose column and bound proteins were eluted with increasing concentrations of KCl. The fractions were analyzed for the presence of EF-1 on SDS-PAGE followed by immunoblotting using anti-EF-1 antibodies. The fractions containing near homogeneous EF-1 (as judged by silver staining) were pooled and dialyzed overnight against buffer C and used for further studies.

Binding Assay (EF-1 + SHP-1)-- For binding assays, purified EF-1 from L. donovani and RAW cells were incubated with 25 µl (packed volume) of glutathione-agarose beads containing equal amounts of GST-SHP-1. Binding was accomplished by mixing in 100 µl of binding buffer (50 mM HEPES, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.01% Triton X-100, and 1% glycerol) for 2 h at 4 °C. Beads were collected by centrifugation and washed four times with binding buffer. Bound EF-1 was eluted by boiling beads for 5 min in Laemmli SDS-gel electrophoresis sample buffer and analyzed by SDS-PAGE followed by immunoblotting using anti-EF-1.

Binding Assay (EF-1 + Calmodulin)-- For this binding assay, purified EF-1 from L. donovani and RAW cells was incubated with 25 µl (packed volume) of calmodulin-agarose beads. Binding and analysis of bound EF-1 were performed essentially as described for GST-SHP-1 with minor modifications. Binding buffer contained 2 mM CaCl₂ instead of EDTA.

Phosphatase Assay-- Immunoprecipitated SHP-1 on protein G-Sepharose beads or as GST-SHP-1 on glutathione-Sepharose beads was washed twice with ice-cold phosphatase assay buffer (62 mM HEPES, pH 7.5, 6.25 EDTA, 12.5 mM dithiothreitol) and then incubated at 37 °C for 30 min in 200 µl of phosphatase assay buffer containing 2 mM p-nitrophenyl phosphate (pNPP). Reactions were terminated by addition of 1 ml of 0.2 M NaOH and absorbance was measured at 410 nM.

Preparation of Cytosolic Fractions from Control and Leishmania-infected Macrophages-- Macrophages were either left untreated or infected with Leishmania promastigotes at an approximate parasite to cell ratio of 10:1. After overnight (16 h) incubation, control and infected cells were washed and cytosolic fractions were prepared. Cells were treated with cold hypotonic buffer (20 mM Tris, pH 7.5) containing protease and phosphatase inhibitors and passed through a 22-gauge needle to disrupt cells. Cell debris was removed by low speed centrifugation and supernatant was supplemented with NaCl to a final concentration of 0.15 M. The cytosolic fractions were prepared further by centrifuging supernatants at 100,000 × g for 20 min at 4 °C. These clarified, high speed supernatants were used as cytosolic fractions.

Metabolic Labeling of Leishmania and Immunoprecipitation of Leishmania EF-1 from Infected Macrophages-- L. donovani promastigotes were metabolically labeled with 5 µCi/ml [³⁵S]methionine in methionine-free RPMI 1640 containing 1% nondialyzed fetal calf serum at room temperature. After 16 h of labeling, parasites were washed twice with RPMI to remove unincorporated [³⁵S]methionine and immediately used for infection of macrophages at an approximate parasite to cell ratio of 10:1. After a 16-h incubation, cells were washed extensively with Hanks' balanced salt solution and processed to prepare cytosolic fractions as described before. The cytosolic fraction from infected macrophages was used to immunoprecipitate labeled Leishmania EF-1 essentially as described before.

Production of Leishmania EF-1-specific Antisera-- Polyclonal antisera against Leishmania EF-1 was raised in BALB/c mice. Leishmania EF-1-specific peptide (KTVTYAQSRYD) was coupled to KLH to immunize mice and sera were collected after three booster immunizations.

Immunofluoresence Staining and Confocal Microscopy-- Macrophages grown on coverslips were incubated with L. donovani promastigotes at an approximate parasite to cell ratio of 10:1. After overnight incubation (16 h), control and infected cells were washed with phosphate-buffered saline and fixed at room temperature for 10 min with 2.5% paraformaldehyde. Following washing with phosphate-buffered saline, cells were blocked for 30 min with 1% bovine serum albumin in phosphate-buffered saline containing 0.1% Triton X-100, and incubated with either commercial anti-EF-1 (1:10) or with Leishmania-specific anti-EF-1 (1:100) for 1 h, washed extensively, and stained for 45 min with anti-mouse IgG fluorescein (1:100). After further washing, the coverslips were mounted on glass slides using mounting media containing antifade (2.5% 1,4-diazabiocyclo[2.2.2]octane, 90% glycerol, phosphate-buffered saline, pH 8.0). For staining of EF-1 promastigotes, organisms were transferred to glass slides using cytospin and processed essentially the same way as described above for macrophages. Preparations were examined using a Bio-Rad Radiance Plus confocal microscope (Bio-Rad) equipped with Zeiss Axiovert S100VT, using a ×63 oil immersion objective. Images of 256 × 256 pixels (50 × 50 µm) were acquired using LaserSharp software (Bio-Rad). Sections of 0.2 µm thickness in the z axis (40-50 slices per image) were assembled into stacks and projected using the Scion Image 4.0.2 software. Projections were then processed and merged using Adobe Photoshop 6.0.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Identification of Leishmania EF-1 as a SHP-1-binding Protein-- Initial studies showed that crude lysates from both Leishmania promastigotes and amastigotes contained a factor that activated SHP-1 in vitro (data not shown). To investigate this further, affinity chromatography of Leishmania lysates was carried out using GST-SHP-1 coupled to glutathione-Sepharose as matrix. Two prominent proteins with approximate subunit sizes of 56 and 44 kDa specifically bound to GST-SHP-1 (Fig. 1A). A parallel affinity column consisting of GST-glutathione-Sepharose showed no detectable binding proteins (data not shown). The two bands shown in Fig. 1A were excised from the gel, and tryptic peptide digests were analyzed by mass spectrometry. Whereas the identity of the 44-kDa band is as yet undetermined, eight of the peptides (TATGHLIYK, TIEKFEK, YAWVLDKL, VGYNVEK, SENMPWYK, LPLQDVYK, IGGIGTVPVGR, and KFAEIESKI) sequenced from the 56-kDa silver-stained band were found to match EF-1 from Leishmania braziliensis (NCBInr accession number 5834626) and covered 16.2% of the sequence.

View larger version (25K): [in this window] [in a new window]   Fig. 1.   Identification of a Leishmania, 56-kDa SHP-1-binding protein as EF-1. A, GST-SHP-1 affinity chromatography. Leishmania promastigotes were lysed in ice-cold lysis buffer A containing a mixture of protease inhibitors for 20 min on ice. All subsequent steps were performed at 4 °C. Lysates were clarified by centrifugation, and supernatants were incubated with GST-SHP-1 affinity beads with end-over-end rotation for 2 h. After incubation, affinity beads were transferred to a column and washed extensively. Bound proteins were released with buffer A containing 0.5 M NaCl. An aliquot of partially purified SHP-1-bound proteins was subjected to SDS-PAGE (12%) followed by silver staining. Positions of SHP-1-binding proteins are shown by arrows (upper arrow, 56 kDa and lower arrow, 44 kDa). B, immunoblotting with anti-EF-1. An aliquot of GST-SHP-1-binding proteins (lane 1), 50 µg of total detergent promastigote lysate (lane 2), and 50 µg of total lysate from the human carcinoma line A431 (lane 3) were separated on SDS-PAGE, transferred to nitrocellulose, and probed with anti-EF-1.

To confirm the identify of the 56-kDa protein, GST-SHP-1-binding proteins were prepared from a Triton X-100 lysate of stationary phase L. donovoni promastigotes. The original Leishmania lysate and the proteins eluted from the column were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-EF-1 antibody. Single bands of identical size in both the Leishmania lysate and in the GST-SHP-1 affinity column eluate (lane 1 and 2 in Fig. 1B) were detected, thus confirming the internal protein sequence data indicating that the 56-kDa SHP-1-binding protein band contained EF-1. Notably, Leishmania EF-1 was observed to be larger than its human homologue (compare lanes 1 and 2 with lane 3 in Fig. 1B). These results identified Leishmania EF-1 as a SHP-1-binding protein.

Leishmania EF-1 and Host EF-1 Show Differential Binding to SHP-1 in Vitro-- To investigate further the interaction of Leishmania EF-1 with SHP-1, EF-1 was purified to near homogeneity from murine macrophages and from Leishmania promastigotes as described under "Experimental Procedures." The fractions containing homogeneous EF-1 as judged by immunoblotting (data not shown) and silver staining (Fig. 2, A and B) were pooled and dialyzed. The purity of these preparations was examined further by tryptic digestion and analysis by mass spectrometry and showed no detectable contamination by other proteins (data not shown). Purified EF-1 from both sources was incubated with GST-SHP-1 and binding assays were performed as described under "Experimental Procedures." The results in Fig. 3A show that EF-1 from Leishmania bound directly and selectively to SHP-1 as comparatively little binding of host EF-1 was detected. To determine that the relatively poor binding of host EF-1 to SHP-1 was not related to loss of functional integrity, both preparations of purified EF-1 were used in binding assays with calmodulin-agarose beads in the presence of Ca²⁺. It has previously been shown that EF-1 from both T. brucei and mammalian origin directly interacts with calmodulin and this interaction seems to require EF-1 in its native conformation (15). As expected, the results in Fig. 3B show that EF-1 from Leishmania and macrophages bound to calmodulin. These findings indicated that purified host EF-1 was conformationally intact and confirmed that the interaction of Leishmania EF-1 and SHP-1 was specific.

View larger version (43K): [in this window] [in a new window]   Fig. 2.   Purification of EF-1s. EF-1 was purified from L. donovani (Ld) (A) and macrophages (B) (RAW264.7 cells) as described under "Experimental Procedures." Shown are silver-stained gels of individual purification steps. Lane 1, cell extract in buffer A before DEAE + CM-Sepharose; lane 2, buffer A insoluble proteins; lane 3, flow through from DEAE + CM-Sepharose; lane 4, pooled fractions eluted from DEAE + CM-Sepharose containing EF-1; lane 5, pooled fractions eluted from phosphocellulose containing EF-1.

View larger version (18K): [in this window] [in a new window]   Fig. 3.   GST-SHP-1 binds selectively to Leishmania EF-1. EF-1 was purified to homogeneity from Leishmania promastigotes (Ld) and from macrophages as described in the legend to Fig. 2 and "Experimental Procedures." For binding to SHP-1 (A), purified EF-1 from either Leishmania or macrophages was incubated with 25 µl (packed volume) of glutathione-agarose beads containing equal amounts of GST-SHP-1. Binding was accomplished by mixing in 100 µl of binding buffer for 2 h at 4 °C. The beads were collected by centrifugation and washed four times with binding buffer. Bound EF-1 was eluted by boiling beads in Laemmli sample buffer, and separated on SDS-PAGE followed by immunoblotting using anti-EF-1. Lanes 1 and 5 represent input amounts of purified EF-1, lanes 2, 3, 6, and 7 are binding assays performed in duplicate. B, binding of EF-1 to calmodulin-agarose was performed essentially as described above for GST-SHP-1 except that binding buffer contained 0.2 mM CaCl2 instead of EDTA. Lanes 1 and 4 represent input amounts of purified EF-1, lanes 2, 3, 5, and 6 are duplicate binding assays. The results shown are from one of two independent experiments that yielded similar results.

Leishmania, but Not Host EF-1 Is a SHP-1 Activator-- Specific binding of Leishmania EF-1 to SHP-1 in vitro suggested that it may be a regulator of SHP-1. To examine this possibility, purified Leishmania or macrophage EF-1 were incubated with freshly prepared GST-SHP-1 to measure in vitro activation. After incubation, unbound proteins were removed and affinity beads were assayed for SHP-1 phosphatase activity using pNPP as a substrate as described under "Experimental Procedures." The results shown in Fig. 4A indicated that Leishmania EF-1, but not its mammalian homologue, was capable of activating SHP-1. Quantitatively, the results observed were comparable with those obtained by other investigators using model phosphotyrosyl containing peptides (16) to activate SHP-1 in vitro.

View larger version (18K): [in this window] [in a new window]   Fig. 4.   SHP-1 is specifically activated by Leishmania EF-1. A, in vitro activation of SHP-1. Purified Leishmania or macrophage EF-1 was incubated with freshly prepared GST-SHP-1 as described under "Experimental Procedures." After incubation, nonbound proteins were removed and affinity beads were assayed for SHP-1 phosphatase activity using pNPP as a substrate. Relative phosphatase activity was assessed by measuring changes in absorbance at 410 nm. B, in vivo activation of macrophage SHP-1. Approximately 1 µg of purified EF-1 prepared from either Leishmania or macrophages or an equivalent amount of bovine serum albumin was incubated separately with Profect 1 reagent in serum-free media to prepare protein-Profect 1 complexes for delivery to RAW264.7 cells (~2 × 106) according to the manufacturer's instructions. After 2-3 h of incubation, cells were lysed in buffer C containing a mixture of protease inhibitors for 20 min on ice and incubated with anti-SHP-1 for 2 h at 4 °C. Immune complexes were recovered using protein A-Sepharose and after extensive washing with buffer C, immune complexes were assayed for phosphatase activity using pNPP as a substrate. The results shown are from one of three independent experiments that yielded similar results.

We also examined whether Leishmania EF-1 was able to activate SHP-1 in vivo. Purified EF-1 from Leishmania, macrophages, or an equivalent amount of bovine serum albumin were mixed separately with Profect 1 reagent in serum-free medium for delivery to macrophages. After 2-3 h of incubation, cells were lysed and immunoprecipitated for SHP-1. Immune complexes were recovered using protein A-Sepharose and after extensive washing, immune complexes were assayed for phosphatase activity using pNPP as a substrate. (Control rabbit serum brought down no SHP-1 activity, data not shown.) As shown in Fig. 4B, delivery of Leishmania EF-1 to macrophages resulted in SHP-1 activation in vivo. In contrast, activation of SHP-1 was not observed when purified macrophage EF-1 or bovine serum albumin were used as control proteins (Fig. 4B).

Leishmania EF-1 Accesses the Cytosol of Infected Macrophages-- SHP-1 is predominantly a cytosolic protein, whereas Leishmania reside within a membrane-bound vacuole. This raises an important question of whether a factor from vacuole-bound Leishmania could access cytosolic SHP-1. To examine the subcellular distribution of Leishmania EF-1 in infected macrophages, Leishmania promastigotes were biosynthetically labeled with [³⁵S]methionine, washed to remove unincorporated isotope, and immediately used to infect macrophages. After overnight infection, cells were disrupted and cytosolic fractions were isolated as described under "Experimental Procedures." EF-1 was immunoprecipitated from the cytosolic, infected cells under native conditions. Immunoprecipitated proteins were separated by SDS-PAGE and detected by autoradiography. Anti-EF-1 precipitated a protein of the correct size for Leishmania EF-1 (Fig. 5A, lane 2) suggesting the presence of Leishmania EF-1 in cytosol of infected macrophages. No [³⁵S]methionine-labeled proteins were precipitated using irrelevant antibody (Fig. 5A, lane 1). To control for the possibility that disruption of phagolysosomes during cell fractionation resulted in the release of EF-1, cytosolic fractions were examined for the presence of mature cathepsin D, a marker of phagolysosomes. The absence of detectable cathepsin D in the cytosol of infected cells (Fig. 5B, lane 1) suggests that any disruption of phagolysosomes was negligible and thus did not account for the presence of Leishmania EF-1 this fraction.

View larger version (35K): [in this window] [in a new window]   Fig. 5.   Detection of Leishmania EF-1 in the cytosol of infected macrophages. A, autoradiograph of immunoprecipitated EF-1. [35S]Methionine-labeled promastigotes were used to infect ~4 × 106 macrophages at a parasite to cell ratio of 10:1. After incubation for 16 h, cells were processed to isolate a cytosolic fraction for immunoprecipitation using anti-EF-1 or isotype-matched irrelevant antibody. Immunoprecipitated proteins were separated by SDS-PAGE and detected by autoradiography. Lane 1, irrelevant antibody; lane 2, anti-EF-1. B, immunoblotting to detect cathepsin D in the cytosolic fraction of infected macrophages. Approximately 100 µg of proteins from the cytosolic or pellet (containing phagosomes) fractions from infected macrophages were precipitated using ice-cold trichloroacetic acid (10% final). Trichloroacetic acid precipitates were washed with cold acetone, air dried, solublized in sample buffer, and separated by SDS-PAGE followed by transfer to nitrocellulose. The membranes were probed with anti-cathepsin D antibodies. Lane 1, cytosolic proteins; lane 2, proteins from the pellet fraction. C, specificity of Leishmania EF-1 anti-peptide antibody. Approximately 50 µg of Triton X-100-soluble extracts from RAW264.7 cells or Leishmania promastigotes were separated by SDS-PAGE and transferred to nitrocellulose. Membranes were probed either with Leishmania EF-1 anti-peptide antibodies or commercial anti-EF-1. Lane 1, Leishmania cell lysate probed with anti-Leishmania EF-1 anti-peptide antibodies; lane 2, macrophage cell lysate probed with anti-Leishmania EF-1 anti-peptide antibodies; lane 3, macrophage cell lysate probed with commercial anti-EF-1 antibodies. D, approximately 100 µg of cytosolic proteins from infected macrophages were processed for immunoblotting as described above and probed with Leishmania EF-1-specific anti-peptide antibodies. The results shown are from one of three independent experiments that yielded similar results.

The presence of Leishmania EF-1 in cytosol of infected macrophages was also investigated using polyclonal antibody raised against Leishmania EF-1 peptide. The specificity of this antibody for Leishmania EF-1 was established by immunoblotting using total cell lysates of Leishmania and macrophages. The presence of a single band in the region of Leishmania EF-1 in lysates of Leishmania and no detectable band in lysates of macrophages (Fig. 5C, compare lanes 1 and 2) clearly shows that this antiserum is highly specific for Leishmania EF-1. The specificity of anti-Leishmania EF-1 was confirmed using purified EF-1 from Leishmania and macrophages (data not shown). When the cytosolic fraction from infected macrophages was subjected to immunoblotting with this anti-peptide antiserum, the results showed (Fig. 5D) the presence of Leishmania EF-1 in this fraction.

Direct Localization of Leishmania EF-1 in Infected Macrophages-- Scanning, confocal, immunofluorescence microscopy using antipeptide antisera was used to independently confirm the presence of Leishmania EF-1 in the cytosol of infected macrophages. Infected and control macrophages grown on coverslips were fixed, permeabilized, and processed for immunofluoresence using either anti-peptide antiserum specific for Leishmania EF-1 or commercial anti-EF-1 antiserum that recognizes both Leishmania and mammalian EF-1. Using Leishmania-specific anti-peptide antiserum, the results shown in Fig. 6, panels 2 and 3, demonstrate Leishmania EF-1 in the cytosol of infected macrophages. As expected, staining of control, noninfected macrophages using the Leishmania-specific antiserum showed no signal (Fig. 6, panel 5), however, control cells showed intense, diffuse fluorescence when commercial anti-EF-1 antibody was used for staining (Fig. 6, panel 7). Taken together with the immunoprecipitation and Western blotting findings, direct detection using confocal microscopy, provides compelling evidence indicating the presence of Leishmania EF-1 in the cytosolic fraction of infected macrophages.

View larger version (79K): [in this window] [in a new window]   Fig. 6.   Subcellular localization of Leishmania EF-1 in infected macrophages using confocal, immunofluorescence microscopy. Macrophages were grown on coverslips and either untreated or infected with L. donovani promastigotes for 16 h. Monolayers were then washed and control (panels 4-7) and infected (panels 1-3) macrophages were fixed with paraformaldehyde, permeabilized using Triton X-100, and stained with either Leishmania EF-1-specific antibodies (panels 2 and 5) or anti-EF-1 commercial antibodies (panel 7). Panels 1, 4 (infected macrophages), and 6 (noninfected) represent differential interference contrast images. Panel 3 represents superimposition of the images in panels 1 and 2. Arrows in panels 1-3 mark the localization of Leishmania in infected cells. The results shown are from one of two independent experiments that yielded similar results.

Leishmania EF-1 Associates with Host SHP-1 in Vivo-- The findings that Leishmania EF-1 bound to SHP-1 in vitro and evidence that it accessed the cytosol of infected cells, suggested that it may target SHP-1 in vivo. To examine this possibility, macrophages were infected with promastigotes for 14-16 h. Cytosolic fractions were then prepared from control and infected cells for immunoprecipitation of SHP-1. Immune complexes were separated on SDS-PAGE under nonreducing conditions followed by transfer to nitrocellulose. Immunoblot analysis carried out using anti-EF-1. (Fig. 7, lane 4) showed that Leishmania EF-1 was associated with SHP-1 in vivo, whereas the association of host-EF-1 with host SHP-1 was not detectable.

View larger version (46K): [in this window] [in a new window]   Fig. 7.   In vivo association of Leishmania EF-1 with host-SHP-1. A, macrophages were either left untreated (Ld) or infected with Leishmania promastigotes (+Ld) at an approximate parasite to cell ratio of 10:1. After overnight (16 h) incubation, control and infected cells were washed and cytosolic fractions were prepared as described under "Experimental Procedures." The cytosolic fractions were incubated with either rabbit anti-SHP-1 antibodies (lanes 3 and 4) or normal rabbit serum (lanes 1 and 2) for immunoprecipitation. Immune complexes were separated on nonreduced SDS-PAGE followed by transfer to nitrocellulose and probed with anti-EF-1. Lanes 1 and 3 are noninfected macrophages; lanes 2 and 4 are Leishmania-infected macrophages. The position of Leishmania EF-1 is indicated by an arrow. B, immunoblotting to detect cathepsin D in the cytosolic and particulate fractions from infected macrophages was carried out as described in the legend to Fig. 5B. Lane 1, cytosolic proteins (100 µg); lane 2, proteins from the pellet fraction (100 µg). The results shown are from one of three independent experiments that yielded similar results.

Leishmania EF-1 Attenuates IFN--induced Activation of iNOS Expression in Macrophages-- In parallel with its ability to activate SHP-1, we examined whether the introduction of EF-1 into cells would impact macrophage activation. Purified Leishmania or macrophage EF-1 was introduced into macrophages using Profect 1 reagent. After incubation for 2 h, macrophages were stimulated with murine IFN-. Cells were then lysed, separated on SDS-PAGE, transferred to nitrocellulose, and probed with anti-iNOS. As shown in Fig. 8, the delivery of purified, native Leishmania EF-1, but not the corresponding host protein into cells blocked the induction of iNOS expression in response to cell treatment with interferon-. The same blot was stripped and reprobed with anti-actin to control for protein loading. Thus, Leishmania EF-1 was able to recapitulate the deactivated phenotype of Leishmania-infected macrophages.

View larger version (39K): [in this window] [in a new window]   Fig. 8.   Leishmania EF-1 attenuates IFN--induced activation of iNOS expression in macrophages. Purified Leishmania or macrophage EF-1 was introduced into macrophages using Profect 1 reagent as described in the legend to Fig. 4B. After incubation for 2 h, macrophages were incubated with 5 units of murine IFN- for 5 h at 37 °C. Cells were assayed for the expression of iNOS essentially as described (4). The same blot was stripped and reprobed with anti-actin to control for protein loading. Lane 1, control cells; lane 2, cells incubated with IFN-; lane 3, preincubation with Leishmania EF-1 followed by IFN-; and lane 4, preincubation with macrophage EF-1 followed by IFN-. The results shown are from one of three independent experiments that yielded similar results.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Results from several recent studies have suggested that the protein-tyrosine phosphatase SHP-1 plays a role in the pathogenesis of Leishmania infection (4, 6, 7). Based upon the particular finding that infection of macrophages with Leishmania results in SHP-1 activation (4, 7), we sought to determine whether a Leishmania activator of SHP-1 could be found. To identify potential SHP-1 interacting protein(s) from Leishmania, affinity chromatography of Leishmania lysates was carried out using GST-SHP-1 coupled to glutathione-Sepharose. This resulted in the isolation of a 56-kDa SHP-1-binding protein that was identified as EF-1 (Fig. 1).

The finding that SHP-1 and Leishmania EF-1 were binding partners was unexpected because EF-1 is a highly conserved, ubiquitously expressed protein in all eukaryotic cells with a diverse range of regulatory properties (15, 17-19). Certainly the role that EF-1 is best known for, if not its most important one, is as a GTP-binding protein involved in regulating the rate and fidelity of protein translation (17, 18). EF-1 exists as a multimeric complex in which the  subunit binds to both GTP and aminoacyl-tRNA, whereas the  and  subunits are involved in GDP-GTP exchange. EF-1 is present in a significant molar excess in comparison to the other subunits and this has led to the suggestion that excess, uncomplexed EF-1 is available to participate in a range of other activities. For example, EF-1 has been shown to regulate cell motility by assembling actin filaments (20) and to regulate the activity of phosphatidylinositol 4-kinase (21). The latter is likely related to the ability of EF-1 to modulate actin organization because phosphatidylinositol 4,5-bisphosphate regulates actin filament structure through effects on actin-binding proteins (22). EF-1 from T. brucei and rabbit reticulocytes has been show to bind calmodulin, although EF-1 as the translational complex fails to do so (15). Localization of EF-1 to the nucleus has led to the suggestion that it may regulate transcription (23). In addition, EF-1 has been shown to be a novel substrate of Rho-associated kinase (24) and it is known that Rho family proteins are involved in regulating phagocytosis (25). The recent finding that EF-1 is a phagosome-associated protein also suggests a potential regulatory role in phagocytosis (26).

Given that EF-1 is both highly conserved and ubiquitously expressed, it was important to determine whether host EF-1 also interacted with SHP-1. Of note was the finding that Leishmania EF-1 migrated more slowly than its human homologue during SDS-PAGE (Fig. 1B), suggesting the possibilities of structural and functional differences. To examine this question further, L. donovani EF-1 and macrophage EF-1 were purified by electrophoresis homogeneity (Fig. 2) and used to investigate possible direct interactions with GST-SHP-1. The results shown in Fig. 3A clearly show that SHP-1 binds preferentially to EF-1 from Leishmania, as very little binding of macrophage EF-1 was observed. It has previously been shown that EF-1 of Trypanosoma brucei and mammalian origins directly interacts with calmodulin and this interaction seems to require EF-1 in its native conformation (15). Hence, as a positive control, binding assays were performed using purified EF-1s and calmodulin-agarose beads. The findings that both macrophage and Leishmania EF-1 bound to calmodulin (Fig. 3B) clearly showed that the purification scheme did not disturb the functional integrity of macrophage EF-1. Taken together, the data show that SHP-1 interacts selectively with Leishmania EF-1 and suggest important structural and functional differences between these otherwise highly homologous proteins.

The specificity of binding of the phosphatase to Leishmania EF-1 suggested that the latter may be a unique SHP-1 regulator. Indeed, just as the Leishmania protein interacted specifically with SHP-1, we found that it functioned as a SHP-1-activating protein both in vitro (Fig. 4A) and in vivo (Fig. 4B), whereas macrophage EF-1 had no such activities. The findings discussed thus far suggested a potential model in which Leishmania EF-1 functions as a virulence factor by activating SHP-1 leading to macrophage deactivation. The requirement in this model for an interaction between these two proteins had to be reconciled with the fact that SHP-1 is predominantly cytosolic in distribution whereas Leishmania reside within a membrane-bound vacuole. The question of whether Leishmania EF-1 could access the macrophage cytosol was addressed using three independent approaches and the evidence from each indicated the presence of Leishmania EF-1 in the cytosol of infected cells. These approaches included: 1) infection of macrophages with ³⁵S-labeled Leishmania followed by immunoprecipitation of labeled EF-1 from cytosolic fractions (Fig. 5A); 2) immunoblotting of the cytosol from infected cells using anti-peptide antiserum specific for Leishmania EF-1 (Fig. 5D); and 3) direct detection of Leishmania EF-1 in the cytosol of infected macrophages using Leishmania EF-1-specific antiserum combined with confocal microscopy (Fig. 6).

These findings indicate that Leishmania EF-1 was exported from the phagosome where it could target host cell proteins. To examine whether Leishmania EF-1 interacted with host SHP-1 in vivo, SHP-1 was immunoprecipitated from cytosol of Leishmania-infected macrophages followed by immunoblotting using anti-EF-1. The results (Fig. 7B) clearly showed that Leishmania EF-1 associated with SHP-1 in vivo, whereas the association of host EF-1 with host SHP-1 was not detectable. It is known that the mature form of cathepsin D is present in the lumen of L. donovani containing phagosomes (27, 28). Hence, cathepsin D was used as a marker of phagosome disruption that may have occurred during preparation of cytosolic fractions from infected macrophages. This analysis showed that the subcellular fractionation did not lead to phagosome disruption as no cathesin D was detected in the cytosol of infected cells even after prolonged exposure of membranes to film (Fig. 5B).

To investigate the importance of the interaction of Leishmania EF-1 with SHP-1, we examined whether the introduction of EF-1 into cells would impact cell activation. The results of this analysis showed that introduction of purified, native Leishmania EF-1, but not the corresponding host protein into cells blocked the induction of iNOS expression in response to cell treatment with interferon- (Fig. 8). Thus, Leishmania EF-1 was able to recapitulate the deactivated phenotype of Leishmania-infected macrophages (4). Taken together, these results show that Leishmania EF-1 is a novel SHP-1 regulator capable of inducing macrophage deactivation. In light of the findings that activation of host SHP-1 appears to be associated with progressive leishmaniasis (4, 6-8) these results strongly suggest that Leishmania EF-1 contributes to disease pathogenesis.

The identification of Leishmania EF-1 as a regulator of host SHP-1 suggests that it may be a novel virulence factor. It also suggests a new paradigm for chronic intracellular infection in which microbial factors directly modulate the activity of host cell regulatory proteins leading to cell deactivation. Clearly, the findings that vanadate treatment reverses the deactivated phenotype of Leishmania-infected macrophages (4) and that SHP-1-deficient cells and mice show enhanced resistance to Leishmania infection (8) are consistent with such a mechanism. A model such as this raises at least two important questions. First, how does EF-1 from vacuole-bound Leishmania cross two membranes (the parasite plasma membrane and the parasitophorous vacuole) to access cytosolic SHP-1? Second, what is the mechanism of phosphatase activation?

Observations addressing the export of macromolecules from Leishmania phagosomes are limited. However, because Leishmania and other intracellular pathogens that reside within phagosomes must access the cytosol to acquire essential nutrients, it seems highly likely that there must be mechanisms by which pathogen-derived molecules can travel in the opposite direction. In this regard, recent work suggests that numerous Mycobacterium bovis BCG proteins are released from phagosomes and can be found in various intracellular compartments (29). Leishmania are known to export a large range of proteins and other factors. For example, both amastigotes and promastigotes secrete a complex range of glycoconjugates including lipophosphoglycan that are surface expressed and secreted (30). Leishmania also export a range of proteophosphoglycans important for interactions within the sandfly gut and for virulence in mammals. Several of these factors are released into phagosomes (31-35) and at least two of these have also been detected in parasite-free vesicles within macrophages (31, 34). Leishmania use a conventional eukaryotic secretory pathway to translocate proteins with signal sequences into the endoplasmic reticulum (36). However, proteins exported by Leishmania that lack a signal sequence have also been identified such as the family of hydrophilic acylated surface proteins. Recently, an acylation-dependent process of protein export in Leishmania involving both palmitoylation and myristoylation has been described for the hydrophilic acylated surface protein (37). It has recently been shown that Leishmania phagosomes can access macromolecules from the macrophage cytosol (38) and Leishmania porins have been described that act to create permeable phagosomes (39). In regard to export of EF-1 from the phagosome, this is unlikely to involve a classical secretory mechanism because the predicted amino acid sequence of EF-1 shows no classical signal sequence for secretion. Hence, this likely involves a nonclassical secretory pathway, perhaps acylation-dependent or otherwise.

As to the mechanism by which Leishmania EF-1 activates SHP-1, it is known that SHP-1 activity is increased as a result of the binding of its tandem Src homology 2 domains to tyrosine-phosphorylated, immunoreceptor tyrosine-based inhibitory motifs (ITIM) within regulatory proteins (11, 12). Our findings that Leishmania EF-1 is tyrosine phosphorylated and that the sequence contains two canonical ITIM motifs² is consistent with such a model. This mechanism has to be reconciled, however, with the fact that these ITIMs are conserved within mammalian EF-1,² which does not activate SHP-1 (Fig. 4). Structural differences between these homologues may account for these divergent activities. For example, in addition to a difference in molecular size (Fig. 1), alignment of mammalian and the EF-1 of Leishmania revealed several significant structural differences that could conceivably make these ITIMs or other motifs unavailable in the host protein. This analysis showed² that despite its slower migration during SDS-PAGE the Leishmania protein has a shorter amino acid sequence compared with mammalian EF-1 by virtue of a 12-amino acid deletion. Comparison of the sequences showed several other critical amino acid substitutions that could contribute to structural and functional differences.

Other than activation by ITIMs, the activity of SHP-1 may also be influenced by its phosphorylation on tyrosine (40, 41) and by interactions with phospholipids (42, 43). Thus, an additional possibility to consider is that the binding of Leishmania EF-1 to SHP-1 may influence the subcellular distribution of the phosphatase and its proximity to a microdomain such as a lipid raft enriched in an activating tyrosine kinases or phospholipid.

In summary, this study has demonstrated a selective interaction between SHP-1 and Leishmania EF-1 and has identified the latter as a novel SHP-1 regulator. By virtue of the fact that this interaction leads to macrophage deactivation, Leishmania EF-1 is identified as a candidate virulence factor. Evidence that Leishmania EF-1 may be a novel virulence determinant combined with its significant structural and functional differences when compared with the corresponding host protein, suggest that it may be an attractive target for anti-Leishmania drug or vaccine development. This potential may be even greater given the essential requirement for EF-1 in protein synthesis and other critical cell functions.

	ACKNOWLEDGEMENT

The skillful technical assistance of Christopher Walsh is gratefully acknowledged.

	FOOTNOTES

^* This work was supported by Canadian Institutes of Health Research Grants FRN-38005 (to D. N.) and MOP-8633 (to N. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence may be addressed: Div. of Infectious Diseases, University of British Columbia, Rm. 452D, 2733 Heather St., Vancouver, British Columbia V5Z 3J5, Canada. E-mail: dnandan@interchange.ubc.ca.

^** To whom correspondence may be addressed: Div. of Infectious Diseases, University of British Columbia, Rm. 452D, 2733 Heather St., Vancouver, British Columbia V5Z 3J5, Canada. Tel.: 604-875-4347; Fax: 604-875-4013; E-mail: ethan@interchange.ubc.ca.

Published, JBC Papers in Press, October 15, 2002, DOI 10.1074/jbc.M209210200

² D. Nandan, A. Cherkasov, T. Yi, and N. Reiner, submitted for publication.

	ABBREVIATIONS

The abbreviations used are: SHP-1, Src homology 2 domain containing tyrosine phosphatase; EF-1, elongation factor-1; iNOS, inducible nitric-oxide synthase; GST, glutathione S-transferase; pNPP, p-nitrophenyl phosphate; IFN-, interferon-; ITIM, immunoreceptor tyrosine-based inhibitory motif.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Halle, M. A. Gomez, M. Stuible, H. Shimizu, W. R. McMaster, M. Olivier, and M. L. Tremblay The Leishmania Surface Protease GP63 Cleaves Multiple Intracellular Proteins and Actively Participates in p38 Mitogen-activated Protein Kinase Inactivation J. Biol. Chem., March 13, 2009; 284(11): 6893 - 6908. [Abstract] [Full Text] [PDF]

				F. F. Tuon, V. S. Amato, H. A. Bacha, T. AlMusawi, M. I. Duarte, and V. Amato Neto Toll-Like Receptors and Leishmaniasis Infect. Immun., March 1, 2008; 76(3): 866 - 872. [Full Text] [PDF]

				U. Gaur, S. C. Roberts, R. P. Dalvi, I. Corraliza, B. Ullman, and M. E. Wilson An Effect of Parasite-Encoded Arginase on the Outcome of Murine Cutaneous Leishmaniasis J. Immunol., December 15, 2007; 179(12): 8446 - 8453. [Abstract] [Full Text] [PDF]

				H. K. Chang, C. Thalhofer, B. A. Duerkop, J. S. Mehling, S. Verma, K. J. Gollob, R. Almeida, and M. E. Wilson Oxidant Generation by Single Infected Monocytes after Short-Term Fluorescence Labeling of a Protozoan Parasite Infect. Immun., February 1, 2007; 75(2): 1017 - 1024. [Abstract] [Full Text] [PDF]

				D. R. A. Martins, S. M. B. Jeronimo, J. E. Donelson, and M. E. Wilson Leishmania chagasi T-Cell Antigens Identified through a Double Library Screen Infect. Immun., December 1, 2006; 74(12): 6940 - 6948. [Abstract] [Full Text] [PDF]

				K. Fan, M. Zhou, M. K. Pathak, D. J. Lindner, C. Z. Altuntas, V. K. Tuohy, E. C. Borden, and T. Yi Sodium Stibogluconate Interacts with IL-2 in Anti-Renca Tumor Action via a T Cell-Dependent Mechanism in Connection with Induction of Tumor-Infiltrating Macrophages J. Immunol., November 15, 2005; 175(10): 7003 - 7008. [Abstract] [Full Text] [PDF]

				M. Olivier, D. J. Gregory, and G. Forget Subversion Mechanisms by Which Leishmania Parasites Can Escape the Host Immune Response: a Signaling Point of View Clin. Microbiol. Rev., April 1, 2005; 18(2): 293 - 305. [Abstract] [Full Text] [PDF]

				S. Kamoun-Essghaier, I. Guizani, J. M. Strub, A. Van Dorsselaer, K. Mabrouk, L. Ouelhazi, and K. Dellagi Proteomic Approach for Characterization of Immunodominant Membrane-Associated 30- to 36-Kilodalton Fraction Antigens of Leishmania infantum Promastigotes, Reacting with Sera from Mediterranean Visceral Leishmaniasis Patients Clin. Vaccine Immunol., February 1, 2005; 12(2): 310 - 320. [Abstract] [Full Text] [PDF]

				A. HAILU, T. VAN DER POLL, N. BERHE, and P. A. KAGER ELEVATED PLASMA LEVELS OF INTERFERON (IFN)-{gamma}, IFN-{gamma} INDUCING CYTOKINES, AND IFN-{gamma} INDUCIBLE CXC CHEMOKINES IN VISCERAL LEISHMANIASIS Am J Trop Med Hyg, November 1, 2004; 71(5): 561 - 567. [Abstract] [Full Text] [PDF]

				N. E. Rodriguez, H. K. Chang, and M. E. Wilson Novel Program of Macrophage Gene Expression Induced by Phagocytosis of Leishmania chagasi Infect. Immun., April 1, 2004; 72(4): 2111 - 2122. [Abstract] [Full Text] [PDF]

				A. Awasthi, R. Mathur, A. Khan, B. N. Joshi, N. Jain, S. Sawant, R. Boppana, D. Mitra, and B. Saha CD40 Signaling Is Impaired in L. major-infected Macrophages and Is Rescued by a p38MAPK Activator Establishing a Host-protective Memory T Cell Response J. Exp. Med., April 21, 2003; 197(8): 1037 - 1043. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 277/51/50190    most recent M209210200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nandan, D. Articles by Reiner, N. E. Search for Related Content PubMed PubMed Citation Articles by Nandan, D. Articles by Reiner, N. E. Social Bookmarking                      What's this?